Targeting the interaction between RNA-binding protein HuR and FOXQ1 suppresses breast cancer invasion and metastasis

  • Commun Biol. 2020 Apr 24;3(1):193. doi: 10.1038/s42003-020-0933-1.
Xiaoqing Wu  1  2 ,  Gulhumay Gardashova  1 ,  Lan Lan  1 ,  Shuang Han  1 ,  Cuncong Zhong  3 ,  Rebecca T Marquez  1 ,  Lanjing Wei  4 ,  Spencer Wood  5 ,  Sudeshna Roy  5  6 ,  Ragul Gowthaman  7 ,  John Karanicolas  8 ,  Fei P Gao  9 ,  Dan A Dixon  1  2 ,  Danny R Welch  2  10 ,  Ling Li  11 ,  Min Ji  12 ,  Jeffrey Aubé  5 ,  Liang Xu  13  14  15
Affiliations
  • 1. Department of Molecular Biosciences, The University of Kansas, Lawrence, KS, USA.
  • 2. The University of Kansas Cancer Center, The University of Kansas Medical Center, Kansas City, KS, USA.
  • 3. Department of Electrical Engineering and Computer Science, The University of Kansas, Lawrence, KS, USA.
  • 4. Bioengineering Program, The University of Kansas, Lawrence, KS, USA.
  • 5. Department of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, The University of North Carolina, Chapel Hill, NC, USA.
  • 6. Department of Biomolecular Sciences, School of Pharmacy, University of Mississippi, University, MS, USA.
  • 7. Center for Computational Biology, The University of Kansas, Lawrence, KS, USA.
  • 8. Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, PA, USA.
  • 9. Protein Production Group, NIH COBRE in Protein Structure and Function, The University of Kansas, Lawrence, KS, USA.
  • 10. Department of Cancer Biology, The University of Kansas Medical Center, Kansas City, KS, USA.
  • 11. National Translational Science Center for Molecular Medicine, Department of Cell Biology, School of Basic Medicine, The Air Force Medical University, Xi'an, Shanxi, China.
  • 12. School of Biological Science and Medical Engineering, Southeast University, Nanjing, Jiangsu, China.
  • 13. Department of Molecular Biosciences, The University of Kansas, Lawrence, KS, USA. [email protected].
  • 14. The University of Kansas Cancer Center, The University of Kansas Medical Center, Kansas City, KS, USA. [email protected].
  • 15. Department of Radiation Oncology, The University of Kansas Medical Center, Kansas City, KS, USA. [email protected].
Abstract

Patients diagnosed with Metastatic Breast Cancer have a dismal 5-year survival rate of only 24%. The RNA-binding protein Hu antigen R (HuR) is upregulated in Breast Cancer, and elevated cytoplasmic HuR correlates with high-grade Tumors and poor clinical outcome of Breast Cancer. HuR promotes tumorigenesis by regulating numerous proto-oncogenes, growth factors, and cytokines that support major tumor hallmarks including invasion and metastasis. Here, we report a HuR Inhibitor KH-3, which potently suppresses Breast Cancer cell growth and invasion. Furthermore, KH-3 inhibits Breast Cancer experimental lung metastasis, improves mouse survival, and reduces orthotopic tumor growth. Mechanistically, we identify FOXQ1 as a direct target of HuR. KH-3 disrupts HuR-FOXQ1 mRNA interaction, leading to inhibition of Breast Cancer invasion. Our study suggests that inhibiting HuR is a promising therapeutic strategy for lethal Metastatic Breast Cancer.

Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • 98.20%, Hu Antigen R Inhibitor
    target: HuR
    Research Areas: Cancer